Clinical significance and the difference between programmed death-1 ligand-1 and ligand-2 in patients with esophageal cancer

被引：0
|
作者：
Okadome, Kazuo [1 ]
Baba, Yoshifumi [1 ]
Yagi, Taisuke [1 ]
Kiyozumi, Yuki [1 ]
Eto, Kojiro [1 ]
Hiyoshi, Yukiharu [1 ]
Nagai, Yohei [1 ]
Ishimoto, Takatsugu [1 ]
Iwatsuki, Masaaki [1 ]
Iwagami, Shiro [1 ]
Miyamoto, Yuji [1 ]
Yoshida, Naoya [1 ]
Baba, Hideo [1 ]
机构：
[1] Kumamoto Univ, Kumamoto, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4123
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
    Zhang, Yan
    Li, Jinbao
    Lou, Jingsheng
    Zhou, Ying
    Bo, Lulong
    Zhu, Jiali
    Zhu, Keming
    Wan, Xiaojian
    Cai, Zailong
    Deng, Xiaoming
    CRITICAL CARE, 2011, 15 (01):
  • [22] Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
    Yan Zhang
    Jinbao Li
    Jingsheng Lou
    Ying Zhou
    Lulong Bo
    Jiali Zhu
    Keming Zhu
    Xiaojian Wan
    Zailong Cai
    Xiaoming Deng
    Critical Care, 15
  • [23] Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance
    Long, J.
    Qu, Tao
    Pan, X. F.
    Tang, X.
    Wan, H. H.
    Qiu, P.
    Xu, Yan-Hua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S1188 - S1192
  • [24] Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
    Xu Cheng
    Zhang Zhi-Hong
    中华医学杂志英文版, 2018, 131 (08) : 990 - 993
  • [25] Correlation between Programmed Death-1 Ligand-1 and p53 in Patients with Lung Adenocarcinoma
    Xu, Cheng
    Zhang, Zhi-Hong
    CHINESE MEDICAL JOURNAL, 2018, 131 (08) : 990 - 993
  • [26] Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges
    Yamashita, Kohei
    Iwatsuki, Masaaki
    Ajani, Jaffer A.
    Baba, Hideo
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2020, 4 (04): : 369 - 378
  • [27] Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
    Wu, Changping
    Zhu, Yibei
    Jiang, Jingting
    Zhao, Jiemin
    Zhang, Xue-Guang
    Xu, Ning
    ACTA HISTOCHEMICA, 2006, 108 (01) : 19 - 24
  • [28] Prognostic value of programmed death ligand-1 and programmed death-1 expression in patients with upper tract urothelial carcinoma
    Campedel, Luca
    Comperat, Eva
    Cancel-Tassin, Geraldine
    Varinot, Justine
    Pfister, Christian
    Delcourt, Clara
    Gobet, Francoise
    Roumiguie, Mathieu
    Patard, Pierre-Marie
    Daniel, Gwendoline
    Bigot, Pierre
    Carrouget, Julie
    Eymerit, Caroline
    Larre, Stephane
    Leon, Priscilla
    Durlach, Anne
    Ruffion, Alain
    de Mazancourt, Emilien Seizilles
    Decaussin-Petrucci, Myriam
    Bessede, Thomas
    Lebacle, Cedric
    Ferlicot, Sophie
    Robert, Gregoire
    Vuong, Nam-Son
    Philip, Magali
    Crouzet, Sebastien
    Matillon, Xavier
    Mege-Lechevallier, Florence
    Lang, Herve
    Mouracade, Pascal
    Lindner, Veronique
    Gougis, Paul
    Cussenot, Olivier
    Roupret, Morgan
    Seisen, Thomas
    BJU INTERNATIONAL, 2023, 132 (05) : 581 - 590
  • [29] Programmed Death-1/Programmed Death Ligand-1 Inhibitor-Related Pneumonitis and Radiographic Patterns
    Nishino, Mizuki
    Hatabu, Hiroto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14)
  • [30] Transarterial chemoembolisation enhances programmed death-1 and programmed death ligand-1 expression in hepatocellular carcinoma
    Montasser, A.
    Beaufrere, A.
    Cauchy, F.
    Soubrane, O.
    Colnot, N.
    Tessiore, S.
    Albuquerque, M.
    Paradis, V.
    VIRCHOWS ARCHIV, 2019, 475 : S20 - S20
12345